Navigation Links
FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimer's Disease (AD)
Date:3/26/2008

BOSTON, March 26 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) market, announced that it has entered into a licensing agreement with Massachusetts General Hospital (MGH) for the development and commercialization of agents for diagnosis and treatment of Alzheimer's disease (AD). The licensed technologies, which were co-developed by FluoroPharma and MGH scientists, target multiple biological processes associated with AD. Currently, there is no single diagnostic test that proves a person has AD. Development of new options for early detection and treatment of Alzheimer's has the potential to improve patient care and create new paths for AD management for the more than 5M Americans that suffer from dementia and other cognitive deficits as a result of AD.

"Our molecular imaging approach to AD includes multiple molecular compositions that target AD associated phenomena -- low acetylcholine and amyloid plaque formation. With some agents, it may be possible to improve brain function by inhibiting the breakdown of acetylcholine, and with others we may be able to prevent the formation of amyloid plaque by inhibiting protein misfolding. As PET imaging tracers, these agents also have potential applications in both diagnosis of the disease and monitoring of the therapy, by differentially accumulating in regions of the brain affected by the disease compared to normal brain tissue," explained Dr. David Elmaleh, FluoroPharma's Chairman and Scientific Founder.

"The technology has the potential to be highly effective due to the agents' enhanced accumulation in the brain," said Dr. Kundakovic, FluoroPharma's President. "As PET imaging agents, these compounds may provide valuable information in patients where early diagnostic and therapeutic information is likely to have the greatest benefit."

About FluoroPharma

FluoroPharma is a molecular imaging company engaged in the discovery and development of proprietary products for the PET market. FluoroPharma is advancing three proprietary products for assessment of acute and chronic forms of coronary disease. These agents have been designed to rapidly target either the myocardial cells within the heart or inflamed plaques within the coronary arteries. http://www.fluoropharma.com

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including the company's need for additional funds, the company's dependence on a limited number of imaging compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. FluoroPharma does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE FluoroPharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Honeywell Expands Aclar(R) Production for Pharmaceutical Industry
2. Murad Expands International Presence With Appointment of Danny Guez
3. Sigma-Aldrich Amends Credit Facility and Expands Commercial Paper Program
4. VIE Healthcare Expands Its Operations in the Midwest, and Obtains First Local Client
5. Eating Disorders Program at Lucile Packard Childrens Hospital Expands to Include Young Adults
6. Dollar Thrifty Automotive Group Expands Mobile Managed Services Contract with InfoLogix
7. Life Spine Expands Home Office Space, More Than Doubling Space Occupied
8. Millennium Expands IBD Franchise with Addition of New Development Candidate
9. inVentiv Clinical Expands Operations to Emerging Latin American Region
10. Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally
11. AlphaDetail, Inc. Expands Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology: